Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the possibility of discontinuing TKI treatment. We have...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Zhang, Bin, Chu, Su, Agarwal, Puneet, Campbell, Victoria L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Gaal, Karl, Holyoake, Tessa L., Bhatia, Ravi
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2016
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5146743/
https://ncbi.nlm.nih.gov/pubmed/27621307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-679928
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi